LAMH (Laboratory for Advanced Medicine & Health Group) is an innovative enterprise focused on AI-driven cancer early screening and diagnosis. It was co-founded by international business leaders, top scientists and authoritative doctors, with the concept of "making cancer screening earlier, more accurate, accessible and convenient". Since its establishment, LAMH has raised more than 1 billion RMB in financing. As a global leader in cancer early screening and diagnosis, LAMH cooperates with multiple top cancer centers, universities, and affiliated hospitals. It has published related research results in top international journals such as Nature, Science, Cell and its sub-journals, PNAS, and has established a full product pipeline for early screening and diagnosis of liver cancer, colorectal cancer, lung cancer, and pan-cancer. With the help of AI-driven technology, LAMH is committed to providing users with a full life-cycle service, combining genomics and clinical medicine theory.

LAMH, an independent entity in China, has its headquarters located in Guangzhou Pazhou Center Business District, a research and registration center in Beijing Economic and Technological Development Zone, Southern and Northern Medical Testing Laboratories (ICL) that meet PCR and NGS standards in Guangzhou Biological Island and Beijing Yizhuang respectively, and an IVD GMP factory through NMPA assessment in Guangzhou Science City. Helio Genomics, an independent entity in the United States, is headquartered in Irvine, California, and has a central laboratory certified by CLIA and CAP in Indiana.